AbbVie forecasts 9.5% sales growth in 2026 amid blockbuster launches and pipeline momentum
Earnings Call Insights: AbbVie (ABBV) Q4 2025 Robert Michael, CEO & Chairman of the Board, reported "record net sales...
Tag: ABBV
AbbVie nears five-month low as Humira drives Q4 beat, not Rinvoq
Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025...
AbbVie posts Q4 beat as Humira outperforms
AbbVie (ABBV) posted better-than-expected financials for Q4 2025 as the company’s former best seller, Humira, exceeded...
Earnings Snapshot: AbbVie tops Q4 estimates; initiates FY26 outlook above forecast
*Other Operating Data Consensus Source: Bloomberg
AbbVie in charts: Revenues from Humira -26%, Skyrizi +32%, Rinvoq +29% Y/Y
Seeking AlphaSeeking AlphaSeeking AlphaSeeking Alpha
AbbVie Q4 Preview: Here’s what to expect
AbbVie (ABBV) is expected to report a 23% surge in its fourth-quarter earnings, scheduled for February 4, before the opening...
AbbVie seeks Rinvoq approval to treat vitiligo
AbbVie (ABBV) has submitted applications to the US FDA and the European Medicines Agency seeking an additional indication...
TrumpRx expected to launch on Friday: report
The White House is expected to launch TrumpRx, its newly announced direct-to-consumer platform for pharmaceutical products,...
Merck is said to halt acquisition talks with cancer drug developer Revolution
Merck (MRK) has ended discussions about a potential acquisition of biotech firm Revolution Medicines, The Wall Street...
Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma
Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie...